Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
0.505
+0.010 (2.06%)
At close: Jun 29, 2026, 4:00 PM EDT
0.505
0.00 (0.00%)
After-hours: Jun 29, 2026, 4:10 PM EDT
Genprex Employees
Genprex had 13 employees as of December 31, 2025. The number of employees decreased by 3 or -18.75% compared to the previous year.
Employees
13
Change (1Y)
-3
Growth (1Y)
-18.75%
Revenue / Employee
n/a
Profits / Employee
-$1,286,634
Market Cap
5.35M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| PMGC Holdings | 34 |
| Aptevo Therapeutics | 33 |
| Processa Pharmaceuticals | 12 |
| Decoy Therapeutics | 11 |
| XTL Biopharmaceuticals | 10 |
| Dermata Therapeutics | 9 |
| CNS Pharmaceuticals | 8 |
GNPX News
- 7 days ago - Genprex says CIPO issues Notice of Allowance for patent - TheFly
- 7 days ago - Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer - PRNewsWire
- 12 days ago - Genprex to Participate at BIO International Convention 2026 - PRNewsWire
- 23 days ago - Genprex files $250M mixed securities shelf - TheFly
- 4 weeks ago - Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting - PRNewsWire
- 6 weeks ago - Genprex collaborators present positive preclinical data of GPX-002 in diabetes - TheFly
- 6 weeks ago - Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting - PRNewsWire
- 2 months ago - Genprex receives patent grant from The Israel Patent Office - TheFly